MMP19 and chronic kidney disease: The Tuttle investigation with CKD patients receiving standard care therapies, i.e., RASi and SGLT2i, demonstrated key reductions in the urine-to-creatinine ratio, suggesting possible additional renal protection with existing therapies [11].